HOME >> MEDICINE >> NEWS
Free antiretroviral therapy key to success of AIDS treatment in developing countries

HIV-infected patients starting highly active antiretroviral therapy (HAART) in developing countries have increased mortality rates in the first months on therapy compared with those in developed countries, according to a paper in this week's issue of The Lancet. The authors state that early diagnosis and assessment of treatment eligibility, coupled with free provision of HAART, might reduce this excess mortality.

HAART has substantially improved the prognosis of HIV-infected patients who have access to these drugs. HAART is being scaled up in developing countries but several factors could limit the effectiveness of the therapy in resource-poor settings.

In this study the researchers compared the ART-LINC Collaboration--a network of 18 HAART programmes in Africa, Asia, and South America--with a similar network of 12 HAART programmes in Europe and North America. They found that mortality was higher in low-income settings than in high-income settings. Patients in low-income countries had lower CD4 cell counts (indicating an increased risk of infection) and more advanced clinical disease when they started treatment. However, the authors state that this only partly explains the higher mortality. They believe accompanying illnesses (comorbidities) such as tuberculosis that are present in many low-income settings may have increased mortality. They also found that the provision of treatment free of charge in low-income settings was strongly associated with lower mortality.

Author Dr Matthias Egger (University of Berne, Switzerland) concludes: "Antiretroviral therapy is feasible and effective in low income settings, but, compared with industrialized countries, mortality is high in the first months. Eligibility for antiretroviral treatment and the need for treatment of tuberculosis should be determined earlier, and HAART should be started before serious comorbidities develop."

In an accompanying Editorial, The Lancet comments: "The start of th
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
9-Mar-2006


Page: 1 2

Related medicine news :

1. Study shows interruption of antiretroviral therapy increases risk of disease and death
2. No advantage for four-drug antiretroviral regimen vs. three-drug for initial treatment of HIV-1
3. Sub-Saharan Africans with HIV may achieve favorable levels of antiretroviral therapy adherence
4. Saving antiretroviral treatment in long-term HIV-positive patients
5. Access to antiretrovirals unlikely to reduce HIV infection rates
6. Study sets new gold standard for initial antiretroviral treatment of HIV infection
7. International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy
8. HIV mortality in India drops with introduction of generic antiretroviral therapy
9. Highly active antiretrovirals for HIV can substantially reduce rates of AIDS
10. Chemotherapy with bevacizumab increases risk of blood clots in arteries
11. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone

Post Your Comments:
(Date:4/27/2015)... Launched by a group of ... consumers a way to connect to top local ... a patent-pending Pick Your Price matching algorithm, clients ... laser hair removal and dermal fillers on days ... in their schedules. This allows clients to take ...
(Date:4/26/2015)... has released a new blog post explaining how to find ... to find low cost auto insurance is by comparing quotes. ... in a simple and convenient way. It is no longer ... prices. All the details are now freely available to anyone ... possible to compare online car insurance quotes on a single ...
(Date:4/26/2015)... India Network Foundation, a non-profit organization in the ... the Asian Indian community in the United States and ... two decades. The India News Network Digest of 1990s ... world with the latest news items from India, the ... Forum Digest, edited and contributed by Sheela Murthy, helped ...
(Date:4/26/2015)... 2015 MidSouth Pain Treatment Center ... Southeast. MidSouth Pain Treatment Center is a comprehensive pain ... Oxford and Jackson, two ambulatory surgery centers in Germantown ... and Cordova locations. , Dr. Michael Steuer , ... medicine to help people, and when I discovered that ...
(Date:4/25/2015)... Washington, D.C. (PRWEB) April 25, 2015 ... for Bangladesh Worker Safety issues the following statement following ... 7.8 earthquake hit Kathmandu, Nepal, resulting in the deaths ... this massive earthquake were felt across Nepal, Bangladesh, India ... to offer my heartfelt condolences to the people of ...
Breaking Medicine News(10 mins):Health News:ZendyBeauty Is Pleased to Announce the Expansion and Rebranding of the Company as ZendyHealth.com 2Health News:Finding Low Cost Auto Insurance - An Online Guide Provides Tips 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 3Health News:Growing Pains for MidSouth Pain Treatment Center 2
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... , April 23, 2015 Once again, BeaconMedaes ... our commitment to patient safety. BeaconMedaes, priority ... against infectious disease. The next generation Zone ... gas sensors are now mounted in the assembly, allowing ... to open ceiling tiles potentially releasing dust spores and ...
(Date:4/23/2015)... -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its ... on Thursday, April 30, 2015, after the close of U.S.-based ... officer, will host a conference call to review the results ... (PT). The press release and a live ... a link that is posted on the home page and ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
Cached News: